About me
Elaine Lippmann, J.D., is a Principal at Leavitt Partners based on Washington, D.C., bringing more than 15 years of leadership experience at the U.S. Food and Drug Administration (FDA) and deep expertise in pharmaceutical regulatory policy to her client work. Elaine most recently served in a leadership role with the Office of Regulatory Policy within the Center for Drug Evaluation and Research (CDER). She is widely recognized as one of FDA’s foremost legal authorities on postmarketing safety, including Risk Evaluation and Mitigation Strategies (REMS), safety labeling, and postmarketing requirements. She has worked closely with industry, clinicians, and patient groups to resolve complex regulatory challenges and shape national policy.
